While molecular testing beyond EGFR and ALK is not currently recommended as standard of care in NSCLC (18), more comprehensive genomic testing will likely become cheaper and more accessible in the future, minimizing time and tissue requirements in efforts to better personalize therapy (49, 50). This evidence concerns the gene ALK and non-small cell lung carcinoma.